Novo Nordisk A/S research snapshot
NVO AI stock analysis currently sees Novo Nordisk as a high-margin diabetes and obesity-care leader with a large GLP-1 franchise, rapid Wegovy pill adoption, and meaningful near-term pressure from lower realized prices, Eli Lilly competition, and pipeline setbacks including the July 31, 2026 ZEUS trial miss. At the August 2, 2026 data cutoff, NVO last closed at $47.08 on July 31, 2026, down 8.78% after the ziltivekimab Phase 3 miss, and the mechanically verified market capitalization was about $208.62 billion. This NVO AI stock analysis uses source-backed facts, scenario ranges, and risk controls. It is informational research, not investment advice.
Current price
$47.08
Market cap
$208.62 billion
AI score
64 / 100
Rating
High-margin metabolic-care franchise under pricing, competitive, and pipeline pressure
Trend status
Event-driven correction; price near the 200-day average; Q2 results due August 5, 2026
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Novo Nordisk converts peptide science, clinical evidence, regulatory approvals, manufacturing, and commercial access into recurring revenue in diabetes, obesity, and rare disease care with high margins. | High |
| Moat | Patents, clinical evidence, trusted brands, device and peptide know-how, manufacturing scale, and global access reinforce each other, but the moat is being tested by Eli Lilly, lower realized prices, and exclusivity losses. | Medium-high |
| Management | Mike Doustdar and the leadership team should be judged on pricing discipline, Wegovy pill and HD execution, CagriSema progress, capacity returns, and whether pipeline setbacks like ZEUS are contained rather than systemic. | Medium |
| Financial trend | FY2025 sales grew 6.4% to DKK 309.1 billion and net profit grew 1.4% to DKK 102.4 billion. Q1 2026 reported sales rose 32% at CER, but adjusted sales fell 4% and adjusted operating profit fell 6% at CER after excluding a USD 4.2 billion 340B reversal. | High |
| Valuation | At $47.08, NVO trades near 11.1x trailing earnings and about 22.4x trailing free cash flow per ADR with a 2.7% dividend yield. Forward PE near 15.3x reflects consensus adjusted EPS declines for 2026. | Medium |
| Technical trend | NVO fell 8.78% to $47.08 on July 31, 2026 after the ZEUS trial miss, closing just above its 50-day and 200-day averages of $46.84 and $46.95 with RSI near 43.2. The short-term setup is neutral to cautious after the event-driven drop. | Medium |
| Risk level | Risk is medium-high because lower realized prices, Eli Lilly and generic competition, reimbursement and policy, patent exposure, pipeline execution, rising net debt from capacity spending, and currency can all affect earnings. | Medium-high |
| AI confidence | Reported results, price, share count, and valuation inputs are well documented. Confidence is lower for exact price outcomes because clinical, policy, and competitive events can move pharmaceutical shares sharply. | High data confidence |
| Investment certainty | Medium-low certainty. NVO has a durable franchise, but a buy decision now requires an explicit view on pricing, market share, patent timing, pipeline execution, and the required margin of safety after two 2026 trial setbacks. | Medium-low |
NVO AI stock forecast
The NVO AI stock forecast uses scenario ranges, not a precise prediction. A three-year model audited with financial_rigor.py used the $47.08 price, an approximately $3.55 FY2025 diluted EPS equivalent, and distinct growth and terminal multiple assumptions. It produces a bearish area near $26 to $30, a base area near $46 to $52, and a bullish area near $72 to $80.
$72 to $80 over three years
More likely if Wegovy pill and Wegovy HD keep expanding the treated population, obesity volume growth offsets lower realized prices, CagriSema and other pipeline assets deliver, US price pressure stabilizes, and investors re-rate NVO toward a mid-to-high-teens earnings multiple.
$46 to $52 over three years
More likely if adjusted earnings stay roughly flat to low single digit after 2026 guidance of -4% to -12% at CER, price pressure remains manageable, the capacity buildout normalizes, and the market values NVO near 12x to 13x earnings.
$26 to $30 over three years
More likely if realized-price declines outrun volume growth, Eli Lilly or lower-cost alternatives keep taking share, patent losses accelerate, CagriSema or other candidates disappoint, or the earnings multiple contracts toward single digits.
NVO AI technical analysis
NVO AI technical analysis is cautious as of the August 2, 2026 cutoff. StockAnalysis recorded a July 31, 2026 close of $47.08, down 8.78% after the ZEUS trial miss. StockAnalysis statistics showed a 14-day RSI near 43.2, a 50-day simple moving average of $46.84, and a 200-day average of $46.95. Investing.com technical data was not reachable at the cutoff, so moving averages and momentum come from StockAnalysis. Technical levels are snapshots and should be confirmed with live chart data.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $47.08 | StockAnalysis listed the July 31, 2026 closing price at $47.08, down 8.78% after the ziltivekimab Phase 3 miss announced that day. |
| Near support | $46.80 to $47.00 | The 50-day simple average was $46.84 and the 200-day simple average was $46.95, clustering just below price and forming the first support area to monitor. |
| Major support | $44.90 to $45.90 | Late-May closes ranged near $44.19 to $45.58. A sustained break below the moving-average cluster would likely target this zone. |
| Near resistance | $49.20 to $49.70 | July 24 to July 28 highs reached about $49.52 to $49.96, creating the first upside test after the event-driven drop. |
| Major resistance | $51.00 to $51.70 | The July 30 close was $51.61, and the pre-drop consolidation traded near $50.32 to $51.61, making this the zone needed to repair the gap. |
| 50-day moving average | $46.84 simple | Price closed marginally above the 50-day simple average, so short-term trend confirmation was incomplete after the drop. |
| 200-day moving average | $46.95 simple | Price remained just above the 200-day simple average, keeping the longer-term trend technically intact but untested. |
| Momentum | 14-day RSI near 43.2 | RSI moved below neutral after the July 31 drop, arguing for confirmation rather than assuming momentum is bullish. |
| Volume | 26.7 million shares on July 31 | The drop occurred on about 2.8x the 20-day average volume of roughly 9.4 million shares, confirming event-driven selling. |
| Volatility | 52-week range $35.12 to $64.16, beta about 0.36 | Reported volatility is moderate, but trial, reimbursement, policy, and earnings events can produce sharp, fast moves. |
| Invalidation | Close below $46.80, then $45.90 | A break below the 50-day and 200-day average cluster weakens the setup. A sustained break below $45.90 calls for a fresh fundamental and technical review. |
NVO AI trading strategy
The NVO AI trading strategy is a rules-based research framework for a pharmaceutical company facing strong metabolic-care demand, lower realized prices, and event-driven risk from clinical, policy, and earnings news. It is not personalized advice and should be paired with live quotes, position sizing, filings, and an event calendar.
Watch for NVO to reclaim the $49.20 to $49.70 area and hold above the 50-day and 200-day averages with volume confirmation before treating the July 31 drop as a completed pullback.
A close below $46.80 should weaken the setup. A sustained break below $45.90 should invalidate the recovery thesis until reassessed.
If NVO stabilizes near the 50-day or 200-day average after the ZEUS-driven drop, compare the reaction with Wegovy pill and HD volume, obesity-market share, realized-price evidence, and the August 5 Q2 results.
Do not average down without a defined loss limit. A technical support level is not a substitute for evidence that the earnings thesis remains intact.
Track adjusted sales and operating profit at CER, Wegovy pill and HD adoption, CagriSema progress, obesity-market share, gross margin, capital spending, net debt, Q2 results on August 5, 2026, and any regulatory, reimbursement, or patent developments.
Reduce confidence if reported growth keeps depending on non-recurring items, if adjusted sales and operating profit keep declining, if pipeline data disappoint, or if volume growth cannot offset price and market-share pressure.
Investment research summary
Novo Nordisk earns recurring medicine revenue by pairing peptide innovation, clinical evidence, regulatory approvals, manufacturing, and commercial access for chronic diabetes, obesity, and rare disease care.
The moat rests on trusted brands, clinical data, intellectual property, device and manufacturing expertise, global distribution, and payer relationships. It weakens when competitors offer better outcomes, access, or prices, as the CagriSema setback and the ZEUS miss show.
The thesis fails if realized prices fall faster than volume rises, Eli Lilly or generics take share, patents open markets to lower-cost alternatives, pipeline assets such as CagriSema or ziltivekimab disappoint, or the large capacity buildout fails to earn adequate returns.
Management must balance growth investment with pricing discipline, capacity returns, clinical productivity, and honest treatment of non-recurring items. The test is durable adjusted earnings, not only prescription volume.
Obesity and diabetes care address large chronic-disease needs and can grow for years. The same opportunity attracts large competitors, payer scrutiny, policy attention, and rapid innovation cycles, which raise execution risk.
At $47.08 the multiple is low versus history, but consensus adjusted EPS is expected to fall in 2026 and pipeline setbacks reduce confidence in a fast re-rating. Margin of safety depends on execution and pricing, not on the size of the GLP-1 market alone.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| NVO closing price | $47.08 on July 31, 2026, down 8.78% | StockAnalysis historical prices | August 2, 2026 |
| Market capitalization | $208.62 billion, verified as $47.08 x about 4.44 billion shares | financial_rigor.py market-cap verification | August 2, 2026 |
| FY2025 net sales | DKK 309.064 billion, up 6.4% | StockAnalysis financials and Novo Nordisk Annual Report 2025 | August 2, 2026 |
| FY2025 net profit | DKK 102.434 billion, up 1.4% | StockAnalysis financials and Novo Nordisk Annual Report 2025 | August 2, 2026 |
| FY2025 free cash flow | DKK 58.962 billion (operating cash flow DKK 119.102 billion less capital expenditure DKK 60.140 billion) | StockAnalysis cash flow statements | August 2, 2026 |
| FY2025 obesity-care sales | DKK 82.347 billion, up about 26% | StockAnalysis segment metrics | August 2, 2026 |
| Q1 2026 reported and adjusted sales | DKK 96.823 billion reported, DKK 70.063 billion adjusted | Novo Nordisk Q1 2026 financial report | August 2, 2026 |
| 2026 adjusted sales and operating profit outlook | -4% to -12% at CER after Q1 update | Novo Nordisk Q1 2026 financial report | August 2, 2026 |
| ZEUS Phase 3 result | Ziltivekimab did not reduce MACE versus placebo (hazard ratio 0.99; 95% CI 0.88 to 1.11) in more than 6,300 patients; 2026 adjusted operating profit outlook unchanged; non-cash impairment in Q3 2026 | Nasdaq/RTTNews coverage of the Novo Nordisk announcement | August 2, 2026 |
| Technical snapshot | RSI near 43.2, 50-day SMA $46.84, 200-day SMA $46.95 | StockAnalysis statistics | August 2, 2026 |
| Analyst consensus | Buy from 14 analysts, average price target $47.23; 2026 consensus revenue DKK 294.02 billion and adjusted EPS DKK 21.01 | StockAnalysis forecast | August 2, 2026 |
This page is an informational research tool, not investment advice or a recommendation to buy or sell any security. Forecast ranges are scenarios based on available data and assumptions. They can be wrong, and readers should verify current information and consider their own objectives and risk tolerance.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
